|

Lorlatinib Clinical Trials

7 actively recruiting trials across 3 locations

Also known as: 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, LOBRENA, Lorbrena, Lorviqua, PF 06463922 +2 more

Pipeline

Early 1: 1Phase 2: 2Phase 3: 1Phase 1/2: 1

Top Sponsors

  • The Netherlands Cancer Institute1
  • Sichuan Cancer Hospital and Research Institute1
  • Pfizer1
  • Nationwide Children's Hospital1
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer6
  • Lung Cancer4
  • Infant Type Hemispheric Glioma1
  • ALK+ Non-Small-Cell Lung Carcinoma1
  • WHO Grade IV Glioma1

Other4 trials

A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib
Phase 2
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
N/A
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Birmingham, Alabama1 trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Aurora, Colorado1 trial

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Children's Hospital Colorado

Early 1

Middletown, New Jersey1 trial

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.